Biology subjects

Zaza, A.

Publications and source records attributed to Zaza, A..

6 recordsLinked to original sources

bioRxiv2026

Species-Dependent Limitations of Murine Myocardium for Investigating the Combined Inotropic Effects of SERCA2a Stimulation and Myofilament Ca2+ Sensitization

Impaired sarcoplasmic reticulum Ca2+ handling and myofilament function both contribute to contractile dysfunction in heart failure. A previous study in failing human myocardium showed that combining the SERCA2a activator istaroxime (ISTA) with the Ca2+ sensitizer levosimendan (LEVO) produces greater positive inotropy than either drug alone. However, human multicellular preparations did not allow comprehensive investigation of the underlying cellular mechanisms. We therefore assessed contractile performance and Ca2+ dynamics in murine multicellular myocardial preparations and ventricular cardiomyocytes treated with ISTA (20 M), LEVO (0.5 M), or their combination. ISTA improved developed force, contraction-relaxation kinetics, and mechanical restitution. These effects were associated with increased Ca2+ transient amplitude, accelerated Ca2+ rise and decay, and enhanced sarcoplasmic reticulum reloading. Adding LEVO produced no further mechanical benefit and only minor changes in Ca2+ handling. LEVO alone elicited heterogeneous contractile responses and increased myofilament Ca2+ sensitivity in only a minority of cardiomyocytes, while consistently accelerating Ca2+ transient decay. This effect was reproduced by the phosphodiesterase-3 inhibitor cilostamide, after which LEVO caused no significant additional change, consistent with a contribution of downstream cAMP-PKA signaling to the acceleration of Ca2+ removal. Thus, limited murine responsiveness to LEVO-mediated myofilament sensitization prevented mechanistic reconstruction of the additive inotropic effect observed in human myocardium, highlighting a species-dependent limitation of the mouse model for studying this combined therapy.

physiology↗

bioRxiv2025

Cellular consequences of non-ablative radiotherapy, a novel approach to ventricular tachycardias

BackgroundRadiotherapy (RT) with a single focused application of ionizing radiation (STAR) has been suggested as a non-invasive alternative to radiofrequency in ablating ventricular tachycardia (VT). Emerging data reveal that STAR may suppress VT without substrate destruction, by enhancing impulse conduction instead, through increased expression of NaV1.5 channels and connexin 43. AimsTo investigate electrophysiology and intracellular Ca2+ dynamics in cardiomyocytes (CMs) from mice subjected to in-vivo RT. The emerging data led us to evaluate biochemical changes potentially linking electrophysiological response to ionizing irradiation. MethodsCMs isolated 2 weeks after RT with low-dose (15 Gy) or high-dose (25 Gy) were compared to those of sham-treated mice (CTRL). We evaluated: i) INaT and INasus properties; ii) AP parameters, including the prevalence of Early After-Depolarizations (EADs); iii) intracellular Ca2+ dynamics; iv) CaMKII phosphorylation and v) ROS content. Results25 Gy RT i) increased INaT and, to a larger extent, INasus (increased INasus/INaT ratio); ii) increased AP amplitude, +dV/dtmax and duration (APD) and facilitated EADs; iii) depressed intracellular Ca2+ dynamics. 15 Gy RT had similar but smaller effects (dose-dependency). 25 Gy RT reduced CaMKII phosphorylation but increased cell ROS content, thus providing a mechanism for INaL enhancement. ConclusionsThe results support the view that STAR may supress VT by increasing conduction velocity, with APD prolongation providing an additional mechanism. On the other hand, INasus enhancement (likely by ROS) and Ca2+ handling depression may impair electrical stability and contractility in the irradiated region.

physiology↗

bioRxiv2024

RvD1 and LXA4 inhibitory effects on cardiac voltage-gated potassium channels

AimsThe resolution of inflammation is modulated by specialized pro-resolving lipid mediators (SPMs), which can be modified in some cardiovascular diseases. Among them, RvD1 and LXA4 prevent atrial fibrillation (AF) remodeling in the atria and cardiac hypertrophy, respectively in animal models. However, little is known about their electrophysiological effects on cardiac voltage-gated (VG) ion channels. Methods and resultsWe used the patch-clamp technique in heterologous systems and cardiomyocytes to assess the acute effect of RvD1, and LXA4, on VG potassium currents. In silico simulations were used to predict the effect of current modulation on the atrial and ventricular action potentials (AP). RvD1 and LXA4 reduced IKs (channel KV7.1/KCNE1) in COS-7 cells and guinea-pig cardiomyocytes without modifying its voltage dependence; RvD1 was more potent than LXA4. In heterologous systems, RvD1 was also tested on IKur (channel KV1.5), Ito (channel KV4.3/KChIP2), IKr (channel KV11.1), and IK1 (channel Kir2.1) with the largest inhibitory effect on IKs and IKr. In simulations RvD1 prolonged repolarization significantly in both atrial and ventricular myocytes. ConclusionThe results provide a comprehensive evaluation of RvD1 and LXA4 on cardiac human potassium channels, at pathophysiological relevant concentrations, being RvD1 more potent than LXA4. The predicted effects on the action potential suggest that, along with their antiinflammatory action, RvD1 may reverse AF-induced electrical remodeling in the atria by direct modulation of K+ currents. The same action might instead contribute to ventricular functional remodeling; however, direct evidence for this is missing.

pharmacology and toxicology↗

bioRxiv2023

Early consequences of the phospholamban mutation PLN-R14del+/- in a transgenic mouse model

AimsThe heterozygous phospholamban (PLN) mutation R14del (PLN R14del+/-) is associated with a severe arrhythmogenic cardiomyopathy (ACM) developing in the adult. "Superinhibition" of SERCA2a by PLN R14del is widely assumed to underlie the pathogenesis, but alternative mechanisms such abnormal energy metabolism have also been reported. This work aims to 1) to evaluate Ca2+ dynamics and energy metabolism in a transgenic (TG) mouse model of the mutation prior to cardiomyopathy development; 2) to test whether they are causally connected. Methods and ResultsCa2+ dynamics, energy metabolism parameters, reporters of mitochondrial integrity, energy and redox homeostasis were measured in ventricular myocytes of 8-12 weeks-old, phenotypically silent, TG mice. Mutation effects were compared to pharmacological PLN antagonism and analysed during modulation of sarcoplasmic reticulum (SR) and cytosolic Ca2+ compartments. Transcripts and proteins of relevant signalling pathways were evaluated. The mutation was characterized by hyperdynamic Ca2+ handling, similar to that induced by PLN antagonism. Albeit all components of energy metabolism were depressed at rest, functional signs of mitochondrial damage or energy starvation were absent and cell energy charge was preserved. The response of mitochondrial O2 consumption to SERCA2a blockade was lost in mutant myocytes (SR-mitochondrial uncoupling) and ER-stress signalling was activated. Conclusions1) PLN R14del+/- loses its ability to inhibit SERCA2a, which argues against SERCA2a superinhibition as a mechanism of ACM; 2) depression of resting energy metabolism may at least partly reflect impairment of SR-mitochondrial coupling; 3) ER-stress may be an early factor in the pathogenesis.

physiology↗

bioRxiv2023

Batch Action PoTential Analyser (BAPTA): an open source tool for automated high throughput analysis of cardiac action potentials

The cardiac action potential (AP) is a key species-specific feature of cardiomyocytes that occurs in response to coordinated actions of ion channels. It represents the first step of the cardiac excitation-contraction coupling and it is crucial for cardiomyocyte (CM) physiology. Changes in the cardiac AP may primarily occur as a consequence of diseases or as a direct or unwanted response to drugs. Our ability to quantify these changes defines the reliability of our measurements and its throughput. Cardiac AP parameters are often quantified through manual time-consuming data analysis protocols or custom-made and proprietary data analysis pipelines; to the best of our knowledge, no tools are currently available for automated cardiac AP analysis and AP parameter quantification. Here we introduce a free and open source software tool named Batch Action PoTential Analyser (BAPTA), written in the R language, designed to i) overcome the inherent operator-dependent bias on trace selection affecting reproducibility, ii) vastly improve the throughput of the analyses of large datasets and iii) analyse both spontaneous and triggered APs from CMs of multiple species and origin. We present here four use-cases in which BAPTA can be used at high throughput to investigate the effects of: 1) a disease (cardiomyopathy) on rat CMs, 2) drugs on mouse pacemaker cells, 3) rate-dependency of AP duration in guinea pig CMs and 4) metabolic electrophysiological maturation in human stem-cell-derived CMs. Overall, BAPTA consistently provides faster, more reproducible and scalable readouts which excellently correlate with manual analyses performed by experienced electrophysiologists.

physiology↗

bioRxiv2021

Istaroxime metabolite PST3093 selectively stimulates SERCA2a and reverses disease-induced changes in cardiac function

BackgroundHeart failure (HF) therapeutic toolkit would strongly benefit from the availability of ino-lusitropic agents with a favorable pharmacodynamics and safety profile. Istaroxime is a promising agent, which combines Na+/K+ pump inhibition with SERCA2a stimulation; however, it has a very short half-life and extensive metabolism to a molecule, named PST3093. The present work aims to investigate whether PST3093, still retains the pharmacodynamic and pharmacokinetic properties of its parent compound. MethodsWe studied PST3093 for its effects on SERCA2a and Na+/K+ ATPase activities, Ca2+ dynamics in isolated myocytes and hemodynamic effects in an in-vivo rat model of diabetic (streptozotocin (STZ)-induced) cardiomyopathy. ResultsIstaroxime infusion in HF patients led to accumulation of PST3093 in the plasma; clearance was substantially slower for PST3093 than for istaroxime. In cardiac rat preparations PST3093 did not inhibit the Na+/K+ ATPase activity, but retained SERCA2a stimulatory activity. In in-vivo echocardiographic assessment, PST3093 improved overall cardiac performance and reversed most STZ-induced abnormalities. PST3093 i.v. toxicity was considerably lower than that of istaroxime and it failed to significantly interact with 50 off-targets. ConclusionsOverall, PST3093 is a "selective" SERCA2a activator, the prototype of a novel pharmacodynamic category with a potential in the ino-lusitropic approach to HF with prevailing diastolic dysfunction. Its pharmacodynamics are peculiar and its pharmacokinetics are suitable to prolong the cardiac beneficial effect of istaroxime infusion. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=137 SRC="FIGDIR/small/455204v3_ufig1.gif" ALT="Figure 1"> View larger version (34K): org.highwire.dtl.DTLVardef@bc9220org.highwire.dtl.DTLVardef@1d7a6eorg.highwire.dtl.DTLVardef@1510c71org.highwire.dtl.DTLVardef@7f037_HPS_FORMAT_FIGEXP M_FIG C_FIG

pharmacology and toxicology↗